Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$1.59 - $2.19 $3,975 - $5,475
-2,500 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$1.05 - $2.18 $1,365 - $2,834
1,300 Added 108.33%
2,500 $5,000
Q1 2020

May 15, 2020

BUY
$0.89 - $1.49 $1,068 - $1,788
1,200 New
1,200 $1,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.51B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.